
OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

October 29, 2020

Table of Contents

Clinical Profile Problems Tab Additions 2

Lab Analytes & Panels Additions 2

Medications 5

 Additions 5

 Updates 5

 Maximum Dose Settings 5

Regimens 6

 Additions 6

 Updates 6

 Renamed Regimens 7

Research 7

 Regimen Additions 7

 Updates 7

Billing: CPT and HCPCS Code Updates 8

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

Clinical Profile Problems Tab Additions

The following items are available for documentation in **Problems** and appear on the **Charge Capture Report (CCR)**. *Additional ICD10 codes may display to present the surrounding nodes.*

Problem	ICD10 Code Choice(s)*
Encounter for palliative care	Z51.5 Encounter for palliative care
Patient entered into trial (finding)	Z00.6 Encounter for examination for normal comparison and control in clinical research program
Participant in a clinical trial	Z00.6 Encounter for examination for normal comparison and control in clinical research program

Lab Analytes & Panels Additions

- 1p/19q Tricolor deletion comments
- 1p/19q Tricolor deletion panel
- ALK lung comments
- ALK lung nuclei analyzed
- ALK lung panel
- ALK lung result
- ALL adult FISH PDF
- ALL FISH adult PDF
- ALL FISH child PDF
- ALL pediatric FISH PDF
- Amikacin peak panel
- Amikacin trough
- Amikacin trough panel
- Amikacin, peak
- Amikacin, ug/mL
- AML favorable-risk PDF
- AML FISH PDF
- AML non-favorable risk FISH PDF
- Band 3 fluorescence staining, RBC
- B-cell receptor gene rearrangement (IGK) PCR panel
- Breast panel (Stain) PDF
- CBC/BM Differential (CBC) comments
- CBC/BM Differential (CBC) date performed
- CBC/BM Differential (CBC) HGB
- CBC/BM Differential (CBC) monocytes
- CBC/BM Differential (CBC) performed at
- CBC/BM Differential (CBC) Plts
- CBC/BM Differential (CBC) RBC
- CFBF (16q22) nuclei analyzed
- CFBF (16q22) result
- CDKN2A (p16) deletion for ALL comments
- CDKN2A (p16) deletion for ALL nuclei analyzed
- CDKN2A (p16) deletion for ALL panel
- CDKN2A (p16) deletion for ALL result
- Chromosome 19pq nuclei analyzed
- Chromosome 19pq result
- Chromosome 1pq nuclei analyzed
- Chromosome 1pq result
- Ciprofloxacin, ug/mL
- Clarithromycin, ug/mL
- Clonoseq MRD panel
- COMPASS peripheral blood evaluation comments
- COMPASS peripheral blood evaluation flow cytometry
- COMPASS peripheral blood evaluation morphology
- COMPASS peripheral blood evaluation other
- COMPASS peripheral blood evaluation panel
- Constitutional chromosome analysis
- Creatinine panel, whole blood
- Creatinine, whole blood
- Crossmatch
- Culture, analysis and karyotype (Culture 1) banding
- Culture, analysis and karyotype (Culture 1) culture type
- Culture, analysis and karyotype metaphases analyzed
- Culture, analysis and karyotype metaphases band resolutions
- Culture, analysis and karyotype metaphases counted
- Culture, analysis and karyotype metaphases karyotyped
- CV quant PCR test information
- Diasorin SARS-CoV-2 Ab, IgG
- Donor, west nile virus AB panel
- EGFR (E746-A750del Specific)
- EGFR (E746-A750del Specific) comments
- EGFR (E746-A750del Specific) result
- EGFR amp
- EGFR amp comments
- EGFR amp nuclei analyzed
- EGFR amp result
- Eosinophilia FISH panel
- Eosinophilia FISH PDF
- Eosinophilia FISH PDF

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

- Ethambutol, ug/mL
- Euroimmun SARS-CoV-2 Ab, IgG
- Existing Donor, west nile virus
- FGFR1 (8p11) nuclei analyzed
- FGFR1 (8p11) result
- FGFR3/IgH t(4;14)
- FGFR3/IgH t(4;14) comments
- FGFR3/IgH t(4;14) nuclei analyzed
- FGFR3/IgH t(4;14) result
- FusionSEQ PDF
- GSD SARS-CoV-2 Ab, IgG
- HER2 breast comments
- HER2 breast nuclei analyzed
- HER2 breast panel
- HER2 breast result
- High-grade B-Cell lymphoma FISH reflex comments
- High-grade B-Cell lymphoma FISH reflex panel
- Icterus
- IDK SARS-CoV-2 Ab, IgG
- Insulin, free (Bioactive)
- Insulin, free (Bioactive) panel
- JAK2 Exon 12-14 mutation analysis
- JAK2 Exon 12-14 mutation analysis comments
- JAK2 Exon 12-14 mutation analysis panel
- KRAS mutation analysis
- KRAS mutation analysis - KRAS mutation
- KRAS mutation analysis - Mutation(s)
- KRAS mutation analysis comments
- KRAS mutation analysis panel
- Lipemia
- Lung NGS fusion PDF
- Manual differential total cells counted
- MCH, UUG
- MCH, UUG
- MDS extended FISH PDF
- MDS standard FISH PDF
- MET comments
- MET nuclei analyzed
- MET panel
- MET result
- Morphology analysis panel
- Moxifloxacin
- MPN extended reflex PDF
- MSH6 Del/Dup
- MSH6 Del/Dup clinical relevance
- MSH6 Del/Dup result
- MSH6 mutation and Del/Dup analysis comments
- MSH6 mutation and Del/Dup analysis panel
- MSH6 sequencing
- MSH6 sequencing clinical relevance
- MSH6 sequencing result
- MSI by PCR
- MSI by PCR - microsatellite instability
- MSI by PCR BAT-25
- MSI by PCR BAT-26
- MSI by PCR comments
- MSI by PCR MONO-27
- MSI by PCR NR-21
- MSI by PCR NR-24
- Multiple marker panel
- Multiple markers comments
- MYC (8q24) nuclei analyzed
- MYC (8q24) result
- NeoGenomics Lynch syndrome PDF
- NeoLAB MDS/CMML profile, liquid biopsy PDF
- NeoLAB myeloid disorders PDF
- NeoTYPE AITL/Peripheral T-Cell Lymphoma PDF
- NeoTYPE AML prognostic PDF
- NeoTYPE Breast tumor PDF
- NeoTYPE Cervical tumor PDF
- NeoTYPE CLL prognostic PDF
- NeoTYPE Colorectal tumor PDF
- NeoTYPE discovery profile for solid tumors (Lung tissue) PDF
- NeoTYPE discovery profile for solid tumors (Other tissue) PDF
- NeoTYPE Endometrial tumor PDF
- NeoTYPE Esophageal tumor PDF
- NeoTYPE Gastric tumor PDF
- NeoTYPE GI predictive PDF
- NeoTYPE GIST and Soft tissue tumor PDF
- NeoTYPE Head & Neck tumor PDF
- NeoTYPE HRD+ PDF
- NeoTYPE JMML PDF
- NeoTYPE Liposarcoma fusion PDF
- NeoTYPE Liver/Biliary tumor PDF
- NeoTYPE Lung tumor PDF
- NeoTYPE Lymphoma PDF
- NeoTYPE MDS/CMML PDF
- NeoTYPE Melanoma PDF
- NeoTYPE Myeloid disorders PDF
- NeoTYPE Other Solid tumor PDF
- NeoTYPE Ovarian tumor PDF
- NeoTYPE Pancreas tumor PDF
- NeoTYPE precision profile for solid tumors PDF
- NeoTYPE Thyroid PDF
- NeoTYPE(TM) Colorectal tumor FISH comments
- NeoTYPE(TM) Colorectal tumor FISH panel
- NeoTYPE(TM) other solid tumor FISH comments
- NeoTYPE(TM) other solid tumor FISH panel
- NeoTYPE(TM) other solid tumor PDF
- Neu# (ANC) + IG#
- Neu# (ANC) + IG#
- NGS NTRK1 fusion - Fusion partner

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

- NGS NTRK1 fusion - Fusion read, %
- NGS NTRK1 Fusion - Mutation in fused genes
- NGS NTRK1 fusion - NTRK1 fusion
- NGS NTRK1 Fusion - Point mutations
- NGS NTRK1 Fusion note
- NGS NTRK2 Fusion - Fusion partner
- NGS NTRK2 Fusion - Fusion read, %
- NGS NTRK2 Fusion - Mutation in fused genes
- NGS NTRK2 Fusion - NTRK2 fusion
- NGS NTRK2 Fusion - Point mutations
- NGS NTRK2 Fusion note
- NGS NTRK3 Fusion - Fusion partner
- NGS NTRK3 Fusion - Fusion read, %
- NGS NTRK3 Fusion - Mutation in fused genes
- NGS NTRK3 Fusion - NTRK3 fusion
- NGS NTRK3 Fusion - Point mutations
- NGS NTRK3 Fusion note
- NPM (Exon12) mutation analysis, plasma based Lumeta panel
- NPM1 mutation analysis
- NPM1 mutation analysis - NPM1 mutation
- NPM1 mutation analysis comments
- NPM1 mutation analysis percentage NPM1 mutation
- NTRK FusionSEQ PDF
- NTRK NGS fusion profile
- NTRK NGS fusion profile panel
- Organism ID
- Pan-TRK result
- Pathology/Cytology signed out by
- Pathology/Cytology source
- PDGFRa (4q12) nuclei analyzed
- PDGFRa (4q12) result
- PDGFRb (5q33) nuclei analyzed
- PDGFRb (5q33) result
- PD-L1 22C3 FDA (Keytruda) for Cervical
- PD-L1 22C3 FDA (Keytruda) for Cervical combined positive score
- PD-L1 22C3 FDA (Keytruda) for Cervical comments
- PD-L1 22C3 FDA (Keytruda) for Cervical result
- PD-L1 22C3 FDA (Keytruda) for ESCC (Esophageal Squamous Cell Carcinoma)
- PD-L1 22C3 FDA (Keytruda) for ESCC combined positive score
- PD-L1 22C3 FDA (Keytruda) for ESCC comments
- PD-L1 22C3 FDA (Keytruda) for ESCC result
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA combined positive score
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA comments
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA result
- PD-L1 22C3 FDA (Keytruda) for HNSCC (Head and Neck)
- PD-L1 22C3 FDA (Keytruda) for HNSCC combined positive score
- PD-L1 22C3 FDA (Keytruda) for HNSCC comments
- PD-L1 22C3 FDA (Keytruda) for HNSCC result
- PD-L1 28-8 FDA (Opdivo)
- PD-L1 28-8 FDA (OPDIVO) comments
- PD-L1 28-8 FDA (OPDIVO) result
- PD-L1 28-8 FDA (OPDIVO) tumor stained
- PD-L1 28-8 FDA (Opdivo) tumor type
- PgR
- PgR allred score
- PgR comments
- PgR intensity
- PgR internal control
- PgR result
- PgR tumor stained
- PgR tumor type
- Plasma cell myeloma FISH PDF
- Plasma cell myeloma IgH complex FISH PDF
- Plasma cell myeloma prognostic PDF
- Please note
- Prosigna assay
- Prosigna assay comments
- Prosigna assay lymph nodes
- Prosigna assay result
- Prosigna assay score
- Prosigna assay tumor size
- PTEN (10q23) nuclei analyzed
- PTEN (10q23) result
- RBC Band 3 protein reduction in hereditary spherocytosis panel
- RET nuclei analyzed
- RET result
- Rifampin
- SARS-CoV-2 Ab, IgG panel
- SARS-CoV-2 Ab, IgG, qual
- Signatera MRD for circulating tumor cells panel
- Slow grower AFB susceptibility panel
- Streptomycin, ug/mL
- Transfused product
- Trimethoprim/sulfa, ug/mL
- Urine culture 72hr
- Urine culture oncology panel

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

Medications

Additions

- 9-ING-41 invest IV
- ABBV-647 invest IV
- Afuresertib invest Oral
- AVM0703 invest IV
- BDC-1001 invest IV
- BI 754091 invest IV
- BI 836880 invest IV
- Ceralasertib invest Oral
- EPI-7386 invest Oral
- GRN163L invest IV
- HMPL-689 invest Oral
- Pancrelipase invest Oral
- PRL3-zumab invest IV
- Psilocybin Oral
- Pyrotinib invest Oral
- SGN-B6A invest IV
- SRF617 invest IV
- TP-0184 invest Oral

Updates

Drug Name	Updates
AVB-S6-500 invest IV	10 mL solution and 20 ml solution dispensables are now available
Afuresertib invest Oral	Synonyms GSK2110183 invest and LAE002 invest are now available
Allopurinol Oral	Quick sigs now available: <ul style="list-style-type: none"> • 10 mg/kg/day orally every 8 hours • 300 mg/m2/day orally every 8 hours
GRN163L invest IV	Synonym Imetelstat invest is now available
Hydrocortisone Oral	Formula Doses now available: <ul style="list-style-type: none"> • 10 mg/m2 • 5 mg/m2 • 3 mg/m2 • 2 mg/m2
Lipase-Protease-Amylase Oral Delayed Release 36,000-114,000-180,000	unit: 2 cap orally As Directed now availbale. Instructions added: Take 2 capsules with every meal and 1 capsule with every snack.
MT-51111 invest IV	Quick Sigs now available: <ul style="list-style-type: none"> • 0 mcg/kg intravenously As Directed, • 0 mcg/kg intravenously As Directed every 7 days, • 0.5 mcg/kg intravenously As Directed, • and 0.5 mcg/kg intravenously every 7 days
NKTR-255 invest IV	Dosing unit mcg/kg is now available
NT-17 invest IV	Medication has been renamed to NT-I7 invest
Pemetrexed IV	Billing code J9035 per 10 mg now available for charges prior to 10/1/2020.

Maximum Dose Settings

Drug Name	New Maximum Single Dose	Rounding Rule
Bendamustine IV	300 mg	
Fludarabine IV	30 mg/m2	1 mg
Methotrexate IV	6750 mg (via continuous infusion)	
Pemetrexed IV		None
Topotecan IV	10 mg, 4 mg/m2	

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

Regimens

All active MSH oncology regimens containing the indicated medications below were updated to the FDB medication resolving issues related to patient education access.

- Bevacizumab-bvzr IV
- Trastuzumab-anns IV
- Trastuzumab-dkst IV
- Trastuzumab-pkrb IV
- Trastuzumab-qyyp IV
- Trastuzumab-dttb IV

Additions

The following regimens are now available for ordering in the Regimen Library .

- Ofatumumab SQ D1,8,15 Q28D (Initial, Multiple Sclerosis)
- Ofatumumab SQ Q28D (Maintenance, Multiple Sclerosis)
- Paclitaxel + Cisplatin alternating with Paclitaxel + Etoposide (TP/TE) Q28D
- Paclitaxel Weekly D1,8 Q14D fb Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense
- Pembrolizumab (Dose Banding) + Axitinib Q42D
- Pembrolizumab Q42D (Dose Banding, Adjuvant Melanoma)
- Ofatumumab SQ D1,8,15 Q28D (Initial, Multiple Sclerosis)
- Ofatumumab SQ Q28D (Maintenance, Multiple Sclerosis)
- Paclitaxel + Cisplatin alternating with Paclitaxel + Etoposide (TP/TE) Q28D
- Paclitaxel Weekly D1,8 Q14D fb Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense

Updates

The following regimens are no longer available for ordering in the Regimen Library .

- Ofatumumab (Initial) Q7D
- Ofatumumab (Maintenance) Q28D
- Rituximab IV + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D
- Rituximab IV BIOSIMILAR + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D
- Rituximab IV fb SQ + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D
- Panitumumab D1,15 + Dabrafenib + Trametinib Q28D

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- | | | |
|-----------------------------------|--|----------------------------------|
| • All Problems | • Leukemia, Chronic Lymphocytic (CLL) | • Malignant Pleural Mesothelioma |
| • Breast Cancer | • Lung Cancer, Non-Small Cell (NSCLC) | • Melanoma, Skin |
| • Colon Cancer | • Lymphoma, Non-Hodgkin (NHL) (Parent) | • Multiple Myeloma (MM) |
| • Esophageal Cancer | • Malignant Mesothelioma | • Multiple Sclerosis |
| • Gastric Cancer | | • Rectal Cancer |
| • Gestational Trophoblastic Tumor | | • Renal Cell Carcinoma (RCC) |

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

Renamed Regimens

Previous Name	New Name
Daratumumab + Carfilzomib + Dexamethasone Q28D	Daratumumab IV + Carfilzomib D1,8,15 + Dexamethasone Q28D
Daratumumab + Carfilzomib + Dexamethasone Q28D (C1 Split Dosing)	Daratumumab IV + Carfilzomib D1,8,15 + Dexamethasone Q28D (C1 Split Dosing)
Nivolumab D1,22 + Ipilimumab Q42D (NSCLC Maintenance)	Nivolumab D1,22 + Ipilimumab Q42D (NSCLC Maintenance, Mesothelioma)
Ofatumumab (Initial) Q7D	Ofatumumab Q7D (CLL Refractory Part 1 of 2: Initial)
Ofatumumab (Maintenance) Q28D	Ofatumumab Q28D (CLL Refractory Part 2 of 2: Maintenance)
Rituximab IV + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D	Rituximab IV + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (R-ICE) Q14D
Rituximab IV BIOSIMILAR + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D	Rituximab IV BIOSIMILAR + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (R-ICE) Q14D
Rituximab IV fb SQ + Ifosfamide CIV D4 + Carboplatin D4 + Etoposide D3-5 (R-ICE) Q14D	Rituximab IV fb SQ + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (R-ICE) Q14D
Daratumumab + Carfilzomib + Dexamethasone Q28D (C1 Split Dosing)	Daratumumab IV + Carfilzomib D1,8,15 + Dexamethasone Q28D (C1 Split Dosing)
Daratumumab + Carfilzomib + Dexamethasone Q28D	Daratumumab IV + Carfilzomib D1,8,15 + Dexamethasone Q28D

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 17205	X	X	X	
USOR 18028	X	X	X	Regimen names updated and available for ordering: USOR 18028 Azacitidine (7-Day Schedule) + Alvocidib (IVI) D10 Q28D USOR 18028 Azacitidine (5-2-2 Schedule) + Alvocidib (IVI) D10 Q28D The following regimen is no longer available for ordering: USOR 18028 Decitabine D1-5 + Alvocidib (1-hour IVI) D8 Q28D

OCT_2020 Content Release Highlights | iKnowMedSM Generation 2

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18155		X		
USOR 18161	X		X	
USOR 18164	X		X	
USOR 18190	X			
USOR 18261	X	X	X	
USOR 19004				Regimen cycle length now follows protocol cycle length.
USOR 19009	X	X		
USOR 19021	X	X	X	The recommended Phase 2 dose has been determined.
USOR 19024	X	X		
USOR 19036	X	X		
USOR 19049	X			
USOR 19165	X	X	X	
USOR 19247	X	X	X	
USOR 20144	X	X	X	
USOR 20219	X			

Billing: CPT and HCPCS Code Updates

Medication / Procedure	CPT/HCPCS Code
Smallpox, Monkeypox Vac, Live (PF) Subcutaneous 0.5x to 3.95x 10exp8/0.5 mL	90749 per 0.5 mL
Satralizumab-mwge Subcutaneous	J3590 per 120 mg
Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease	99072